Physician profile
David M Eisinger
NPI 1780036459
$1,979.25
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $65.54 · 2022: $45.11 · 2023: $783 · 2024: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $292.76 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $171.72 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.64 | 2020-2024 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $115.09 | 2023-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $113.28 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $107.04 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $101.88 | 2019-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $100.69 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $96.91 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $87.16 | 2019-2024 | Gardasil 9, Gardasil, Vaxelis |
| Dexcom, INC. | $69.80 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $67.67 | 2023-2024 | Injectafer |
| Exact Sciences Corporation | $61.39 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $60.65 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.28 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $50.36 | 2024 | Rexulti |
| Viiv Healthcare Company | $49.15 | 2024 | Apretude |
| Inspire Medical Systems, INC. | $40.76 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $33.03 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $28.81 | 2019 | |
| Sumitomo Pharma America, INC. | $22.01 | 2024 | Gemtesa |
| Biomarin Pharmaceutical INC. | $21.28 | 2024 | Voxzogo 1.2mg |
| Actelion Pharmaceuticals US, INC. | $19.92 | 2024 | Opsumit, Uptravi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.52 | 2024 | Caplyta |
| Horizon Therapeutics Plc | $19.27 | 2023 | Krystexxa |
| Phadia US INC. | $13.85 | 2024 | Immunocap |
| Idorsia Pharmaceuticals US INC | $13.55 | 2023 | Quviviq |
| Gilead Sciences, INC. | $11.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eisinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.